Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRITON: CHF 5993 vs CHF 1535 in COPD
NCT04320342Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Apr 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of glycopyrronium bromide in chronic obstructive pulmonary disease (COPD), sponsored by Chiesi Farmaceutici S.p.A.. Started Apr 2022; status: completed.
02
Drugs
glycopyrronium bromide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04320342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04320342.